Investors

Press Releases

NASDAQ: ENVB

Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts

Press Releases

Enveric Biosciences Secures New U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

September 15, 2026

Enveric Biosciences to Present at H.C. Wainwright 28th Annual Global Investment Conference

September 1, 2026

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

August 14, 2026

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

August 5, 2026

Enveric Biosciences Welcomes Final FDA Guidance for Psychedelic Drug Development

July 28, 2026

Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit

June 29, 2026

Enveric Biosciences Announces Participation in 2026 BIO International Convention

June 16, 2026

Enveric Biosciences to Participate in the UBS 3rd Virtual CNS Day

June 9, 2026

Enveric Biosciences Initiates Investigational New Drug (IND)-enabling Genotoxicity Studies of Lead Neuroplastogen Candidate EB-003

June 2, 2026

Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003

May 19, 2026

1
2
3
…
20
›